KDR and lung adenocarcinoma: TKIs such as Erlotinib and Gefitinib have no effect on lung adenocarcinoma patients with KRAS mutations; however, combination therapy with Erlotinib and VEGFR-2 inhibitor can help achieve better prognoses for these patients.